Headlines about Adaptimmune Therapeutics PLC (NASDAQ:ADAP) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Adaptimmune Therapeutics PLC earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.5854525725245 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the media stories that may have effected Accern’s scoring:

A number of brokerages have recently weighed in on ADAP. BidaskClub upgraded Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a report on Friday. Zacks Investment Research downgraded Adaptimmune Therapeutics PLC from a “buy” rating to a “hold” rating in a report on Monday, July 17th. Cowen and Company reiterated a “buy” rating on shares of Adaptimmune Therapeutics PLC in a report on Tuesday, June 6th. Finally, ValuEngine upgraded Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Thursday, July 20th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $12.08.

Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) traded down 1.14% on Friday, hitting $5.19. The stock had a trading volume of 142,575 shares. Adaptimmune Therapeutics PLC has a one year low of $3.76 and a one year high of $8.36. The firm has a 50 day moving average price of $5.31 and a 200 day moving average price of $5.01. The company’s market capitalization is $485.36 million.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.24). Adaptimmune Therapeutics PLC had a negative net margin of 438.00% and a negative return on equity of 38.73%. The company had revenue of $3.52 million for the quarter, compared to analyst estimates of $5.43 million. On average, equities research analysts predict that Adaptimmune Therapeutics PLC will post ($1.06) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/25/adaptimmune-therapeutics-plc-adap-earning-somewhat-favorable-press-coverage-study-finds.html.

About Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Insider Buying and Selling by Quarter for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

Receive News & Stock Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related stocks with our FREE daily email newsletter.